SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001819790-23-000030
Filing Date
2023-05-09
Accepted
2023-05-09 16:15:45
Documents
65
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q tars-20230331.htm   iXBRL 10-Q 1221668
2 EX-31.1 exhibit311-33123.htm EX-31.1 12774
3 EX-31.2 exhibit312-33123.htm EX-31.2 13048
4 EX-32.1 exhibit321-33123.htm EX-32.1 9965
5 EX-32.2 exhibit322-33123.htm EX-32.2 9784
  Complete submission text file 0001819790-23-000030.txt   6342209

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tars-20230331.xsd EX-101.SCH 40268
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT tars-20230331_cal.xml EX-101.CAL 61319
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT tars-20230331_def.xml EX-101.DEF 194371
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tars-20230331_lab.xml EX-101.LAB 556352
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tars-20230331_pre.xml EX-101.PRE 357882
59 EXTRACTED XBRL INSTANCE DOCUMENT tars-20230331_htm.xml XML 1072184
Mailing Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618
Business Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618 (949) 409-9820
Tarsus Pharmaceuticals, Inc. (Filer) CIK: 0001819790 (see all company filings)

IRS No.: 814717861 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39614 | Film No.: 23902218
SIC: 2836 Biological Products, (No Diagnostic Substances)